Parathyroid hormone and leptin – new peptides, expanding clinical prospects

Bibliography

• WHITFIELD JF: How to grow bone to treat osteoporosis and mend fractures. Corr. Osteoporosis Rep. (2003) 1:32–40.
   PubMedGoogle Scholar
• ••This is the most recent compendium ofinformation on bone anabolics.
   Google Scholar
• WHITFIELD JF: In: Crowing Bone. Landes Bioscience, Georgetown, TX, USA (2005).
   Google Scholar
• WHITFIELD JF, MORLEY P, WILLICK GE: Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis. Treat. Endociinol (2002) 1:175–190.
   PubMedGoogle Scholar
• WHITFIELD JF, MORLEY P, WILLICK GE: Bone growth stimulators, new tools for treating bone loss and mending fractures. Vitam. Horm. (2002) 65:1–80.
   PubMed Web of Science ®Google Scholar
• DUCY P, AMLING M, TAKEDA S et al:Leptin inhibits bone formation through a hypothalamic relay. Cell (2000) 100:197-207. This is the first paper reporting leptin's indirect, CNS-mediated anti-osteogenic action in obese mice.
   Google Scholar
• BARBIER JR, NEUGEBAUER W, MORLEY P et al: Bioactivities and secondary structures of constrained analogues of human parathyroid hormone: cyclic lactams of the receptor binding region. J. Med. Chem. (1997) 40:1373–1380.
   PubMed Web of Science ®Google Scholar
• WHITFIELD JF, MORLEY P, WILLICK G et al.: Cyclisation by a specific lactam increases the ability of human parathyroid hormone (hPTH)-(1–31) NH2 to stimulate bone growth in ovariectomised rats.' Bone Miner. Res. (1997) 12:1246–1252.
   Google Scholar
• WHITFIELD JF, MORLEY P, WILLICK GE et al: Stimulation of the growth of femoral trabecular bone in ovariectomised rats by the novel parathyroid hormone fragment, hPTH-(1-31)NH2 (ostabolin). Cakil: Tissue Lit. (1996) 58:81–87.
   PubMed Web of Science ®Google Scholar
• MEHTA N, STERN W, STURMER A, BOLAT A, CHEN J, GILLIGAN J: Oral delivery of PTH analogues by a solid dosage formulation. 'Bone Miner Res. (2001) 16:S540.
   Web of Science ®Google Scholar
• ••The first report of an oral, 31 amino acidPTH analogue.
   Google Scholar
• FDA news, October 14 2004.
   Google Scholar
• KOSTENUIK PJ, CAPPARELLI C, MORONY S et al: OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomised rats. Endocrinology (2001) 142:4295–4304.
   PubMed Web of Science ®Google Scholar
• COSMAN F, NIEVES JW, LUCKEY MM, ZION M, WOELFERT L, LINDSAY R: Daily versus cyclic PTH combined with alendronate versus alendronate alone for treatment of osteoporosis. J. Bone Miner Res. (2003) 18:S32.
   Web of Science ®Google Scholar
• HODSMAN AB, FRAHER LJ, WATSON PH et al.: A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. Clin. Endocrinol Metab. (1997) 82:620–628.
   Google Scholar
• CHEN XD, STEWART SA, MANOLAGAS SC, JILKA RL: Dissection of PTH-induced signaling network in osteoblastic cells using a novel bioinformatics approach../. Bone Mther. Res. (2004) 19:S76.
   Web of Science ®Google Scholar
• ALKHIARY YM, GERSTENFELD LC, CULLINANE DM et al.: Parathyroid hormone (1-34; teriparatide) enhances experimental fracture healing. J. Bone Miner. Res. (2003) 18:S24.
   PubMed Web of Science ®Google Scholar
• ANDREASSEN TT, EJERSTED C, OXLUND H: Intermittent parathyroid hormone (1-34) treatment increases callus formation and mechanical strength of healing fractures../. Bone Miner. Res. (1999) 14:960–968.
   PubMed Web of Science ®Google Scholar
• •The first demonstration of a PTH's ability to accelerate fracture healing.
   Google Scholar
• ANDREASSEN TT, FLEDELIUS C, EJERSTED C, OXLUND H: Increase in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone. Acta Orthop. Land. (2001) 72:304–307.
   PubMed Web of Science ®Google Scholar
• ANDREASSEN TT, WILLICK GE, MORLEY P, WHITFIELD JF: Treatment with parathyroid hormone hPTH(1-34), hPTH (1-31), and monocyclic hPTH (1-31) enhances fracture strength and callus amount after withdrawal, fracture strength and callus mechanical quality continue to increase. Cakil Tissue Int. (2004) 74:351–356.
   PubMed Web of Science ®Google Scholar
• KIM HW, JHANG JS: Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomised rats. Iowa Orthop. (1999)19:71–77.
   PubMedGoogle Scholar
• NAKAJIMA A, SHIMOJI N, SHIOMI K et al.: Mechanisms for the enhancement of fracture healing in rats treated intermittent low-dose human parathyroid hormone (1–34).j Bone Miner. Res. (2002) 17:2038–2047.
   Google Scholar
• BONADIO J: Tissue engineering via local gene delivery: update and future prospects for enhancing the technology. Adv. Drug. Deliv. Rev (2000) 44:185–194.
   PubMed Web of Science ®Google Scholar
• BONADIO J, SMILEY E, PATIL P, GOLDSTEIN S: Localized, direct plasmid gene delivery in vivo: prolonged therapy results in reproducible tissue regeneration. Nat. Med. (1999) 5:753–759.
   PubMed Web of Science ®Google Scholar
• FANG J, ZHU YY, SMILEY E et al.: Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc. Natl. Acad. Sci. USA (1996) 93:5753–5758.
   PubMed Web of Science ®Google Scholar
• GOLDSTEIN SA, BONADIO J: Potential role for direct gene transfer in the enhancement of fracture healing. Clin. Orthop. (1998) 355(Suppl.):5154–5162.
   Google Scholar
• ARCHIBECK MJ: The basic science of periprosthetic osteolysis. AAOS Instruct. Course Lect. (2001) 50:185–195.
   PubMedGoogle Scholar
• DAVIES JE: In: Bone Engineering. Em squared Inc., Toronto, ON, Canada (2000).
   Google Scholar
• ELLINGSEN JE, LYNGSTADAAS SP: In: Bio-Implant Interface, CRC Press, Boca Raton, FL, USA (2003).
   Google Scholar
• INGHAM E, FISHER J: Biological reactions to wear debris in total joint replacement. Proc. Inst. Mech. Eng. IH1 (2000) 214:21–37.
   PubMed Web of Science ®Google Scholar
• SKRIPITZ R, ASPENBERG P: Early effect of parathyroid hormone (1-34) on implant fixation. Clin. Orthop. Rel. Res. (2000) 392:427–432.
   Google Scholar
• SKRIPITZ R, ASPENBERG P: Implant fixation enhanced by intermittent treatment with parathyroid hormone. I Bone Joint Surg. (2000) 83B:437–440.
   Web of Science ®Google Scholar
• SKRIPITZ R, ASPENBERG P: Parathyroid hormone (1-34) increases attachment of PMM cement to bone. I Orthop. (2001) 6:540–544.
   Google Scholar
• SHIROTA T, TASHIRO M, OHNO K, YAMAGUCHI A: Effect of intermittent parathyroid hormone (1-34) treatment on the bone response after placement of titanium implants into the tibia of ovariectomised rats. I Ora] Maxillofac. Surg. (2003) 61:471–480.
   PubMed Web of Science ®Google Scholar
• ALLEN MJ, SCHOONMAKER JE, MANN KA et al.: PTH analogs enhance bone formation at a weight-bearing cement-bone interface. 50th Annual Meeting of the Orthopaedic Research Socieoi, San Francisco, USA (2004):Poster 1429.
   Google Scholar
• ASTRAND J, SKRIPITZ R, SKOGLUND B, ASPENBERG P: A rat model for testing pharmacological treatments of pressure-related bone loss. Orthop. (2003) 409:296–305.
   Google Scholar
• ASTRAND J, ASPENBERG P: Reduction of instability-induced bone resorption using bisphosphonates: big doses are needed in rats. Acta Orthop. Scand. (2002) 73:24–30.
   PubMed Web of Science ®Google Scholar
• SHANBHAG AS, HASSELMAN CT, RUBASH HE: The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin. Orthop. (1997) 344:33–43.
   Google Scholar
• THADANI PJ, WAXMAN B, SLADEK E, BARMADA R, GONZALEZ MH: Inhibition of particulate debris-induced osteolysis by alendronate in a rat model. Orthopedics (2002) 25:59–63
   PubMed Web of Science ®Google Scholar
• WHITFIELD JF, CHAKRAVARTHY B: In: Cakium: The Grand-master Cell Signaller. NRC Research Press, Ottawa, ON, Canada (2001).
   Google Scholar
• ORLOFF JJ, KATS Y, URENA P et al: Further evidence for a novel receptor for amino-terminal parathyroid hormone-related protein on keratinocytes and squamous carcinoma cell lines. Endocrinology (1995) 136:3016–3023.
   PubMed Web of Science ®Google Scholar
• WHITFIELD JF, CHAKRVARTHY BL, DURKIN JP et al.: Parathyroid hormone stimulates protein kinase C but not adenylate cyclase in mouse epidermal keratinocytes. I Cell. Physic] (1992) 150:299–303.
   PubMed Web of Science ®Google Scholar
• TU C-L, ODA Y, KOMUVES L, BIKLE D: The role of the calcium-sensing receptor in epidermal differentiation. Cell Calcium (2004) 35:265–273.
   PubMed Web of Science ®Google Scholar
• LOWELL S, JONES P, LE ROUX I, DUNNE J, WATT F: Stimulation of human differentiation by 8-Notch signalling at the boundaries of stem cell clusters. Curr. Biol. (2000) 10:491–500.
   PubMed Web of Science ®Google Scholar
• RANGARAJAN A, TALORA C, OKUYAMA R et al: Notch signalling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO 1 (2001) 20:3427–3436.
   PubMed Web of Science ®Google Scholar
• OKUYAMA R, NGUYEN B-C, TALORA C et al.: High commitment of embryonic keratinocytes to terminal differentiation through Notch 1-caspase 3 regulatory mechanism. Devi.] Cell (2004) 6:551–562.
   PubMed Web of Science ®Google Scholar
• NICKOLOFF BJ, QIN JZ, CHATURVEDI V, DENNING ME BONISH B, MIELE L: Jagged-1 mediated activation of notch signalling induces complete maturation of human keratinocytes through NF-KB and PPAR-y. Cell Death Differ. (2002) 9:642–855.
   Google Scholar
• POTTEN C, WILSON J: Apoptosis, Cambridge University Press, Cambridge, UK (2004).
   Google Scholar
• LEFORT K, DOTTO GP: Notch signalling in the integrated control of keratinocyte growth/differentiation and tumor suppression. Smith. Cancer Biol. (2004) 14:374–386.
   PubMed Web of Science ®Google Scholar
• HANAFIN NM, CHEN TC, HEINRICH G, SEGRE GV, HOLICK MF: Cultured human fibroblasts and not cultured human keratinocytes express a PTH/PTHrP receptor mRNA. J. Invest. Dermatol. (1995) 105:133–137.
   PubMed Web of Science ®Google Scholar
• MAIOLI E, FORTINO V, TORRICELLI C, AREZZINI B, GARDI C: Effect of parathyroid hormone-related protein on fibroblast proliferation and collagen metabolism in human skin. Exp. Dermatol. (2002) 11:302–310.
   PubMed Web of Science ®Google Scholar
• PUN KK, TAM SM: Parathyroid hormone-activated phosphoinositide degradation and calcium channels in human dermal fibroblasts. Biol. Signals (1995) 4:19–23.
   PubMedGoogle Scholar
• HOLICK MF, RAYS, CHEN TC, TIAN X, PERSONS KS: A parathyroid hormone antagonist stimulates epidermal proliferation and hair growth in mice. Proc. Natl. AcadSd. USA (1994) 91:8014–8016.
   PubMed Web of Science ®Google Scholar
• CALVI LM, ADAMS GB, WEILBRECHT KW et al.: Osteoblastic cells regulate the haematopoietic stem cell niche. Nature (2003) 425:841–846.
   PubMed Web of Science ®Google Scholar
• ••The first 'modem' demonstration of aPTH's ability to affect haematopoiesis.
   Google Scholar
• WEBER JM, ADAMS GB, GUZMAN ML et al.: Parathyroid treatment improves survival after bone marrow transplantation and increases osteoblastic expression of the Notch ligand Jagged 1. J. Bone Miner. Res. (2004) 19:S407.
   Web of Science ®Google Scholar
• AHO S: Soluble form of Jagged 1: unique product of epithelial keratinocytes and a regulator of keratinocyte differentiation. I Cell. Biochem. (2004) 92:1271–1281.
   PubMed Web of Science ®Google Scholar
• NICOLAS M, WOLFER A, RAJ K et al.: Notch 1 functions as a tumour suppressor in mouse skin. Nature Gen. (2003) 33:416–421.
   PubMed Web of Science ®Google Scholar
• THELU J, ROSSIO P, FAVIER B: Notch signalling is linked to epidermal cell differentiation in basal cell carcinoma, psoriasis, and wound healing. BMC Dermatol. (2002) 2:7.
   PubMedGoogle Scholar
• ••One of the keys to the cause of psoriasis.
   Google Scholar
• WHITFIELD JF: Taming psoriatic keratinocytes-PTHs' uses go up another notch." Cell. Biochem. (2004) 93:251–256.
   PubMed Web of Science ®Google Scholar
• JUHLIN L, HAGFORSEN E, JUHLIN C: Parathyroid hormone-related protein is localized in the granular layer of normal skin and in the dermal infiltrates of mycosis fungoides but is absent in psoriatic lesions. Acta Berm. Venereol. (1992) 72:81–83.
   PubMed Web of Science ®Google Scholar
• MENON GK, ELIAS PM: Ultrastructural localization of calcium in psoriatic and normal human epidermis. Arch. Dermatol. (1991) 127:57–63.
   PubMed Web of Science ®Google Scholar
• KARVONEN SL, KORKIAMAKI T, YLA-OUTINEN H et al.: Psoriasis and altered calcium metabolism: downregulated capacitative calcium influx and defective calcium-mediated cell signaling in cultured psoriatic keratinocytes." Invest. Dermatol. (2000) 114:693–700.
   Google Scholar
• McKENZIE R, ODA Y, SZEPIETOWSKI JC, BEHNE MJ, MAURO T: Defective cyclic guanosine monophosphate-gated calcium channels and the pathogenesis of psoriasis. Acta Berm. Venereol. (2003) 83:414–418.
   PubMed Web of Science ®Google Scholar
• HOLICK MF, CHIMEH FN, RAY S: Topical PTH (1-34) is a novel, safe and effective treatment for psoriasis: a randomized self-controlled trial and an open trial. Br. .1 Dermatol. (2003) 149:370–376.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration of the ability ofhPTH-(1–34)0H to treat psoriasis.
   Google Scholar
• RIXON RH, WHITFIELD JF: The radioprotective action of parathyroid extract. Int. J. Radiat. Biol. (1961) 3:361–367.
   PubMed Web of Science ®Google Scholar
• •The first indication of PTH having a role In bone marrow function.
   Google Scholar
• CHEN XD, STEWART SA, MANOLAGAS SC, JILKA RL: Dissection of PTH-induced signaling network in osteoblastic cells using a novel bioinformatics approach." Bone Mther. Res. (2004) 19:S76.
   Web of Science ®Google Scholar
• PERRIS AD, MacMANUS JP, WHITFIELD JF, WEISS LA: Parathyroid glands and mitotic stimulation in rat bone marrow after hemorrhage. Am. J. Physiol. (1971) 220:773–778.
   PubMed Web of Science ®Google Scholar
• GALLIEN-LARTIGUE 0, CARREZ D: Induction in vitro de la phase S dans cellules souches multipotentes de la moelle osseuse par f hormone Parathyro-dienne. C. R. Acad. Sci. Herbd. Seances Acad. Sci. Paris (D) (1974) 278:1765–1768.
   PubMedGoogle Scholar
• ••The very first demonstration of PTHbeing able to target haematopoietic stem cells.
   Google Scholar
• OHISHI K, KATAYAMA N, SHIKU H, VARNUM-FINNEY B, BERNSTEIN ID: Notch signaling in hematopoiesis. Sermin. Cell Bevel. Biol. (2003) 14:143–150.
   Google Scholar
• SCHWEISGUTH F: Regulation of Notchsignaling activity. Curr. Biol. (2004) 14:R129–R138.
   PubMed Web of Science ®Google Scholar
• ZHU J, EMERSON SG: A new bone to pick: osteoblasts and haematopoietic stem cell niche. BioEssays (2004) 26:595–599.
   PubMed Web of Science ®Google Scholar
• BOSTROM K, DEMER LL: Regulatory mechanisms in vascular calcification. Grit. Rev Eukaryotic Gene Expr. (2000) 12:151–158.
   Google Scholar
• DEMER LL: Vascular calcification and osteoporosis: inflammatory responses to oxidized lipids. Int. J. Epidenhol. (2002) 31:737–741.
   PubMed Web of Science ®Google Scholar
• DEMER LL, TINTUT Y: Osteopontin: Between a rock and a hard plaque. Circ. Res (1999) 84:250–252.
   PubMed Web of Science ®Google Scholar
• DOHERTY TM, FITZPATRICK LA, INOUE D et al: Molecular endocrine, and genetic mechanisms of arterial calcification. Endocrine Rev. (2004) 25:629–672.
   PubMed Web of Science ®Google Scholar
• ••The most recent collection of informationon vascular ossification.
   Google Scholar
• VATTIKUTI R., TOWLER DA: Osteogenic regulation of vascular calcification: an early perspective. Am. J. Physiol. Endocrinol. Metab. (2004) 286:E686–E696.
   PubMed Web of Science ®Google Scholar
• CHEN NX, MOE SM: Arterial calcification in diabetes. Curr. Diab. Rep. (2003) 3:28–32.
   PubMedGoogle Scholar
• VIRCHOW R: Cellular Pathology: As Based Upon Physiological and Pathological Histology. Dover. New York (1863/1971):408.
   Google Scholar
• LIBBY P: Inflammation in atherosclerosis. Nature (2002) 420:868–874.
   PubMed Web of Science ®Google Scholar
• STEINBERG D: Atherogenesis in perspective: hyper cholesterolemia and inflammation as partners in crime. Nat. Med. (2002) 8:1211–1217.
   PubMed Web of Science ®Google Scholar
• STOCKER R, KEANEY JF: Role of oxidative modifications in atherosclerosis. Physiol. Rev (2004) 84:1381–1478.
   PubMed Web of Science ®Google Scholar
• GROENEVELD EHJ, BURGER EH: Bone morphogenic proteins in human bone regeneration. Eur. Endocrinol. (2000) 142:9–21.
   PubMed Web of Science ®Google Scholar
• ABEDIN M, TINTUT Y, MEMER LL: Vascular calcification: mechanisms and clinical ramifications. Arterioscler. Thromb. Vasc. Biol. (2004) 24:1161–1170.
   PubMed Web of Science ®Google Scholar
• BROSTROMK, WATSON KE, HORNS, WORTHAM HC, HERMAN IM, DEMER LL: Bone morphogenic protein expression in human atherosclerotic lesions. Clin. Invest. (1993) 91:1800–1809.
   Google Scholar
• DEMER LL, TINTUT Y: Mineral exploration: search for the mechanism of vascular calcification and beyond. Arterioscler. Thromb. Vase. Biol. (2003) 23:1739–1743.
   PubMed Web of Science ®Google Scholar
• DEMER LL, TINTUT Y, PARHAMI F: Novel mechanisms in accelerated vascular calcification in renal disease patients. Curr. Opin. Nephrol Hypertens. (2002) 11:437–443.
   PubMed Web of Science ®Google Scholar
• ENGELSE MA, NEELE JM, BRONKERS ALJJ, PANNEKOEK H, DE VRIE CJ: Vascular calcification: expression patterns of the osteoblast-specific gene core binding factor a-1 and the protective factor matrix gla protein in human atherogenesis. Cardiovascular Res. (2001) 52:281–289.
   PubMed Web of Science ®Google Scholar
• FUKUI N, ZHU Y, MALONEY WJ, CLOHISY J, SANDELL LJ: Stimulation of BMP-2 expression by pro-inflammatory cytokines IL-1 and TNF-a in normal and osteoarthritic chondrocytes. Bone Joint Surg. Am. (2003) 85-A\(Suppl. 3):59–66.
   Google Scholar
• JAKOBY MG, SEMENKOVICH CF: The role of osteoprogenitors in vascular calcification. Curr. Opin. Nephrol Hypertens. (2000) 9:11–15.
   PubMed Web of Science ®Google Scholar
• JONO S, NISHIZAWA Y, SHIOI A, MORII H: Parathyroid hormone-related peptide as a local regulator of vascular calcification. Arterioscler. Thromb. Vase. Biol. (1997) 17:1135–1142.
   PubMed Web of Science ®Google Scholar
• ••One of the first assessments of PTH'spossible effects on vascular ossification.
   Google Scholar
• JONO S, PEINADO C, GIACHELLI CM: Phosphorylation of osteopontin is required for inhibition of vascular smooth muscle cell calcification. J. Biol. Chem. (2000) 275:20197–20203.
   PubMed Web of Science ®Google Scholar
• MODY N, TINTUT Y, RADCLIFF K, DERMER LL: Vascular calcification and its relation to bone calcification: possible underlying mechanisms. J. Nucl. Cardiol (2003) 10:177–183.
   PubMed Web of Science ®Google Scholar
• TINTUT Y, ALFONSO Z, SAINT T et al: Multilineage potential of cells from the artery wall. Circulation (2003) 108:2505–2510.
   PubMed Web of Science ®Google Scholar
• WADA T, McKEE MD, STEITZ S, GIACHELLI CM: Calcification of vascular smooth muscle cell cultures: inhibition by osteopontin. Circ. Res. (1999) 84:166–178.
   PubMed Web of Science ®Google Scholar
• ISHIKAWA M, AKISHITA M, KOZAKI Ket al.: Expression of parathyroid hormone-related protein in human and experimental atherosclerotic lesions: functional role in arterial intimal thickening. Atherosclerosis (2000) 152:97–105.
   Google Scholar
• SHAO JS, CHENG SL, CHARLTON-KACHIGIAN N, LOEWY AP, TOWLER DA: Teriparatide human parathyroid hormone (1-34) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice../. Biol. Chem. (2003) 278:50195–50202.
   PubMed Web of Science ®Google Scholar
• ••A very important demonstration of aPTH's ability to inhibit, instead of stimulate, vascular ossification.
   Google Scholar
• MARTIN-VENTURA JL, ORTEGO M, ESBR P, HERNANDEZ-PRESA MA, ORTEGA L, EGIDO J: Possible role of parathyroid hormone-related protein as a proinflammatory cytokine in atherosclerosis. Stroke (2003) 34:1783–1789.
   PubMed Web of Science ®Google Scholar
• NAKAYAMA T, OHTSURU A, ENOMOTO H et al: Coronary atherosclerotic smooth muscle cells over express human parathyroid hormone-related peptides. Biochem. Biophys. Res. Commun. (1994) 200:1028–1035.
   PubMed Web of Science ®Google Scholar
• OZEKI S, OHTSURU A, SETO S et al:Evidence that implicates the parathyroid hormone-related peptide in vascular stenosis. Increased gene expression in the intima of injured carotid arteries and human restenoic coronary lesions. Arterioscler. Thromb. Vase. Biol. (1996) 16:565–575.
   Google Scholar
• DE MIGUEL F, FIASCHI-TAESCH N, LOPEZ-TELAVERA JC et al: The C-terminal region of PTHrP, in addition to the nuclear localization signal, is essential for the intracrine stimulation of proliferation in vascular smooth muscle cells. Endocrinology (2001) 142:4096–4105.
   PubMed Web of Science ®Google Scholar
• FIASCHI-TAESCH N, TAKANE KK, MASTERS S, LOPEZ-VERA JC, STEWART AF: Parathyroid hormone-related protein as a regulator of pRb and the cell cycle in arterial smooth muscle. Circulation (2004) 110:177–185.
   PubMed Web of Science ®Google Scholar
• MASSFELDER T, DANK P, WU TL, VASAVADA R, HELWIG J-J: Opposing mitogenic and anti-mitogenic actions of parathyroid hormone-related protein in vascular smooth muscle cells: a critical role for nuclear targeting. Proc. Natl. Acad. Li. USA (1997) 94:13630–13635.
   PubMed Web of Science ®Google Scholar
• MURRAY TM, RAO LG, DIVIETI P, BRINGHURST FR: Parathyroid hormone secretion and action: Evidence for discrete receptors for the carboxyl-terminal region and related biological actions of carboxyl- terminal ligands. Endocrine Revs. (2005) (In press).
   Google Scholar
• YLITALO R: Bisphosphonates and atherosclerosis. Gen. Pharmacol (2002) 35:287–296.
   Google Scholar
• ••The discovery of the 'bisphosphonateparadox', which is the ability of bisphosphonates to prevent skeletal bone resorption but to reduce vascular bone.
   Google Scholar
• NIITA K, AKIBA T, SUZUKI K et al: Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am. J. Kidney Dis. (2004) 44:680–688.
   PubMed Web of Science ®Google Scholar
• BLUM WF: Leptin: the voice of the adipose tissue. Hormone Res. (1997) 48 (Suppl. 4):2–8.
   Google Scholar
• AHIMA RS, FLIER JS: Leptin. Ann. Rev Physiol (2000) 62:413–437.
   PubMed Web of Science ®Google Scholar
• HIMMS-HAGEN J: Physiological roles of the leptin endocrine system: differences between mice and humans. Grit. Rev Clin. Lab. ScL (1999) 36:575–655.
   PubMed Web of Science ®Google Scholar
• TAKEDA S, ELEFTERIOU F, KARSENTY G: Commen endocrine control of body weight, reproduction, and bone mass. Ann. Rev Nutr. (2003) 23:403–411.
   PubMed Web of Science ®Google Scholar
• TAKEDA S, ELEFTERIOU F, LEVASSEUR R et al: Leptin regulates bone formation via the sympathetic nervous system. Cell (2002) 111:305–317.
   PubMed Web of Science ®Google Scholar
• ••The first indication that intracerebroventricularly injected leptin inhibits bone formation by stimulating adrenergic agonist release.
   Google Scholar
• RAHMOUNI K, HAYNES WG: Leptin and the cardiovascular system. Recent Progr. Holm. Res. (2004) 59:225–244.
   PubMedGoogle Scholar
• BONNET N, BRUNET-IMBAULT B, PARNAUD CJ et al.: 132-Adrenergic agonists have negative effects on bone architecture and density in rat. J. Bone Miner. Res. (2003) 18:S42.
   Web of Science ®Google Scholar
• LAVASSEUR R, SABATIER JP, POTRELBURGOT C, LECOQ B, CREVEUIL C, MARCELLI C: Sympathetic nervous system as transmitter of mechanical loading in bone. John Bone Spine (2003) 70:515–519.
   PubMed Web of Science ®Google Scholar
• PIERROZ DD, BOUXSEIN ML, GLATT V, RIZZOLI R, FERRARI SL: Intermittent PTH and propranolol have synergistic effects on vertebral trabecular bone in ovariectomised mice. J. Bone Miner. Res. (2004) 19:S460.
   Web of Science ®Google Scholar
• PASCO JA, HENRY MJ, SANDERS KM, KOTOWICZ MA, SEEMAN E, NICHOLSON GC: B-Adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong Osteoporosis Study. J. Bone Miner. Res. (2004) 19:19–24.
   PubMed Web of Science ®Google Scholar
• HAMRICK MW: Leptin, bone mass, and the thrifty phenotype. I Bone Miner. Res. (2004) 19:1607–1611.
   PubMed Web of Science ®Google Scholar
• WELT CK, CHAN JL, BULLEN J et al: Recombinant human leptin in women with hypothalamic amenorrhea. N Engl. I Med. (2004) 351:959–962.
   PubMed Web of Science ®Google Scholar
• HAMRICK MW, PENNINGTON C, NEWTON D, XIE D, ISALES C: Leptin deficiency produces contrasting phenotypes in the bones of the limb and spine. Bone (2004) 34:369–371.
   PubMedGoogle Scholar
• TAMASI JA, AREY BJ, BERTOLINI DR, FEYEN JH: Characterization of bone structure in leptin receptor-deficient Zucker (fa/fa) rats. ./. Bone Miner. Res. (2003) 18:1605–1611.
   PubMed Web of Science ®Google Scholar
• BURGUERA B, HOFBAUER LC, THOMAS T et al: Leptin reduces ovariectomy-induced bone loss in rats. Endocrinology (2001) 142:3546–3553.
   PubMed Web of Science ®Google Scholar
• GORDELADZE JO, DREVON CA, SYVERSEN U, RESELAND JE: Leptin stimulates human osteoblastic cell proliferation, de novo collagen synthesis, and mineralization: impact on differentiation markers, apoptosis, and osteoclastic signaling. ./. Cell. Biochem. (2002) 85:825–836.
   PubMed Web of Science ®Google Scholar
• ••A summary of the evidence for leptin'sdirect stimulation of osteogenesis.
   Google Scholar
• HOLLOWAY WR, COLLIER FM, AITKEN CJ et al: Leptin inhibits osteoclast generation. J. Bone Mther. Res. (2002) 17:200–209.
   PubMed Web of Science ®Google Scholar
• LIU C, GROSSMAN A, BAIN S: Leptin stimulates cortical bone formation in obese mice. J. Bone Miner. Res. (1997) 12:S115.
   Web of Science ®Google Scholar
• RESELAND JE, SYVERSEN U, BAKKE I et al: Leptin is exressed in and secreted from primary cultures of human osteoblasts and promotes bone mineralization. J. Bone Miner. Res. (2001) 16:1426–1433.
   PubMed Web of Science ®Google Scholar
• STEPPAN CM, CRAWFORD DT, CHIDSEY-FRINK KL, KE H, SWICK AG: Leptin is a potent stimulator of bone growth in ob/ob mice. Regul Pept. (2000) 92:73–78.
   PubMed Web of Science ®Google Scholar
• ••The first demonstration of the directosteogenic action of leptin in obese mice.
   Google Scholar
• THOMAS T, GORI F, KHOSLA S, JENSEN MD, BURGUERA H, RIGGS BL: Leptin acts on human marrowstromal cells to enhance differentiation to osteoblasts and to inhibit differentiation to adipocytes. Endocrinology (1999) 140:1630–1638.
   PubMed Web of Science ®Google Scholar
• TORDAY JS, SUN H, WANG L, TORRES E: Leptin mediates the parathyroid hormone-related protein paracrine stimulation of foetal lung maturation. Am. I Physiol Lung Cell. Mol Physiol (2002) 282:L405–L410.
   PubMed Web of Science ®Google Scholar
• •An indication that leptin might be a mediator of PTH's osteogenis action.
   Google Scholar
• YAMAUCHI M, SUGIMOTO T, YAMAGUCHI T et al.: Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women. Clin. Endocrinol. (2001) 55:341–347.
   PubMed Web of Science ®Google Scholar
• ROUX C, ARABIA, PORCHER R, GARNERO P: Serum leptin as a determinant of bone resorption in healthy postmenopausal women. Bone (2003) 33:847–852.
   PubMed Web of Science ®Google Scholar
• HADJI P, BOCK K, GOTSCHALK M et al: The influence of serum leptin concentration on bone mass assessed by quantitative ultrasonography in pre- and postmenopausal women. Maturitas (2003) 44:141–148.
   PubMed Web of Science ®Google Scholar
• ODABASI E, OZATA M, TURAN M et al: Plasma leptin concentration in postmenopausal women with osteoporosis. Eur.j Endocrinol. (2002) 142:170–173.
   Web of Science ®Google Scholar
• SAHIN G, POLAT G, BAETHIS S et al: Body composition, bone mineral density, and circulating leptin levels in post-menopausal Turkish women. Rheumatol Int. (2003) 23:87–91.
   PubMed Web of Science ®Google Scholar
• SHAARAWY M, ABASSI AF, HASSAN H, SALEM ME: Relationship between serum leptin concentration and bone mineral density as well as biochemical markers of bone turnover in women with postmenopausal osteoporosis. Fern] Stern. (2003) 79:919–924.
   PubMed Web of Science ®Google Scholar
• PARHAMI F, TINTUT Y, BALLARD A, FOGELMAN AM, DEMER LL: Leptin enhances the calcification of vascular cells. Artery wall as a target of leptin. Circ. Res. (2001) 88: 954–960.
   Google Scholar
• ••A 'red flag' report that leptin stimulatesvascular ossification, which, if confirmed, means that it should be avoided for treating bone loss.
   Google Scholar
• SINGHAL A, FAROOQI S, COLE TJ et al.: Influence of leptin on arterial distensibility. Circulation (2002) 106:1919–1924.
   PubMed Web of Science ®Google Scholar
• FACCIO R, LAM J, AYA K et al: Oligomeric RANKL induces bone formation via the ERK pathway. J. Bone. Miner. Res. (2003) 18:S141.
   Web of Science ®Google Scholar